Dietrich John Pauls - Jul 28, 2021 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
President and CEO, Director
Signature
/s/ Amy Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jul 28, 2021
Transactions value $
$0
Form type
4
Date filed
7/29/2021, 09:07 PM
Next filing
Aug 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 30.8K Jul 28, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +175K $0.00 175K Jul 28, 2021 Common Shares 175K $5.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2 Vests in sixteen nearly equal quarterly installments over four years.